Direct-to-Consumer Laboratory Testing Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.28 Billion |
| Market Size (2029) | USD 5.37 Billion |
| CAGR (2024 - 2029) | 10.35 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Direct-to-Consumer Laboratory Testing Market Analysis
The Direct-to-Consumer Laboratory Testing Market size is estimated at USD 3.28 billion in 2024, and is expected to reach USD 5.37 billion by 2029, growing at a CAGR of 10.35% during the forecast period (2024-2029).
The major factors driving the market are high patient convenience and accessibility, growing technological advancements, and the rising prevalence of chronic diseases like diabetes and cancer.
Direct-to-consumer (DTC) laboratory tests allow patients to collect samples at home, eliminating the need to visit labs or healthcare facilities. DTC also allows consumers to order online anytime, bypassing the traditional healthcare channels. Hence, high patient convenience and accessibility are expected to drive the market during the forecast period.
For instance, according to an article published in the British medical journal in December 2023, as part of a greater commercial shift toward more individualized and consumer-driven healthcare models, DTC testing promises the opportunity for more proactive self-care and personal autonomy. Patients no longer need to rely on doctors' recommendations. Consumers can initiate and obtain pathology tests quickly and conveniently from DTC laboratory tests to make timely management decisions. Hence, due to the high patient convenience and accessibility, the direct-to-consumer laboratory demand is expected to increase and drive the market during the forecast period.
Moreover, the increasing prevalence of chronic diseases such as diabetes increases the demand for direct-to-consumer laboratory testing to manage blood glucose with patient convenience effectively. This will drive the market during the forecast period. For instance, as per the 2022 update from the International Diabetic Federation (IDF), approximately 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Hence, the rising prevalence of chronic diseases such as diabetes increases the demand for direct-to-consumer laboratory tests for efficient management of diabetes, which will drive the market during the forecast period.
Also, the increasing technological advancements, such as at-home kits and mobile apps that increase the adoption of direct-to-consumer laboratory tests, are expected to drive the market during the forecast period.
For instance, in July 2023, Quest Diagnostics, a diagnostic information services provider, reported the launch of Genetic Insights, a consumer-initiated genetic test, now exclusively available through the company's consumer health business at questhealth.com. This test utilizes saliva samples to analyze 36 genes and identify the potential risk of nearly two dozen inheritable conditions. These conditions include breast and colon cancer, various heart and blood disorders, as well as carrier status for cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. Hence, the launch of such technologically advanced direct-to-consumer laboratory tests is expected to drive the market during the forecast period.
Thus, high patient convenience and accessibility of DTC laboratory testing and increasing technological advancements in DTC laboratory testing products are expected to drive the market during the forecast period. However, data privacy concerns and reimbursement issues are expected to restrain the market during the forecast period.
Direct-to-Consumer Laboratory Testing Market Trends
The Genetic Testing Segment is Expected to Hold Significant Market Share During the Forecast Period
Direct-to-consumer genetic tests (DTC-GT) are tests sold directly to consumers to provide information about their genetic information, including ancestry, certain health traits, and health risks, using a saliva sample. DTC-GT improves the patient's convenience, affordability, personal choice, and privacy. The rising prevalence of genetic disorders such as sickle cell anemia, cancer, and cystic fibrosis and increasing strategic activities by the key players are expected to drive the market during the forecast period.
The rising prevalence of genetic disorders and increasing awareness about genetic diseases increase the demand for DTC genetic tests for early identification and proper treatment, which are expected to drive the market during the forecast period. For instance, according to an article published in the Lancet Haematology in August 2023, the number of people living with sickle cell disease around the globe was around 7·74 million in 2022. Similarly, according to the American Cancer Society 2024 update, about 2 million new cancer cases are expected to be diagnosed in the United States in 2024. Hence, the rising prevalence of genetic disorders and growing awareness about genetic disorders are expected to drive the market during the forecast period.
Also, increasing strategic activities such as acquisitions, investments, and new product launches are expected to improve the accessibility and affordability of DTC genetic tests, which will ultimately drive the market during the forecast period. For instance, in May 2023, Grifols, a provider of plasma-derived medicines and innovative diagnostic solutions, reported the launch of AlphaID At Home, a direct-to-consumer program in the United States to screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1) for the identification of chronic obstructive pulmonary disease (COPD). Hence, the launch of such services is expected to increase the accessibility of direct-to-consumer laboratory testing, which will drive the market during the forecast period.
Thus, the rising prevalence of genetic diseases and increasing strategic activities by key players are expected to drive the segment revenue during the forecast period.
North America is Expected to Hold the Significant Market Share During the Forecast Period
The direct-to-consumer laboratory testing market in North America is driven by factors such as the increasing prevalence of chronic diseases such as diabetes, cancer, and thyroid, advanced healthcare infrastructure, and rising strategic activities such as acquisitions and partnerships by key players.
The rising occurrence of chronic diseases like diabetes and hyperthyroidism is driving the demand for direct-to-consumer (DTC) laboratory tests. These tests are used for frequent blood glucose and thyroid hormone monitoring, providing high patient convenience. This trend is expected to propel the market during the forecast period. For instance, according to a Diabetes Canada update from January 2024, around 5.8 million people lived with diabetes in Canada in 2023, and it is estimated to reach 7.4 million by 2033. According to an article published in Cureus in September 2023, the prevalence rate of primary hypothyroidism in the population of the United States ranges from 4% to 8%. Hence, the significant prevalence of diabetes and thyroid is expected to drive the market during the forecast period.
Also, the increasing strategic activities, such as acquisitions by key players to increase the accessibility of direct-to-consumer laboratory testing, will ultimately drive the market during the forecast period. In October 2022, GC LabTech, a subsidiary of GC Biopharma, announced a partnership with 1health.io to offer innovative lab tests directly to consumers. This partnership enables GC LabTech to sell its innovative new health and wellness tests into the direct-to-consumer lab testing market. Hence, such strategic activities increase the accessibility of direct-to-consumer laboratory testing and will drive the market during the forecast period.
Therefore, the increasing prevalence of chronic conditions such as diabetes and hyperthyroidism, as well as the growing number of strategic partnerships, will enhance the accessibility and affordability of direct-to-consumer laboratory tests, thereby driving the market during the forecast period.
Direct-to-Consumer Laboratory Testing Industry Overview
The direct-to-consumer laboratory testing market is fragmented due to the presence of many startups in the field. Direct-to-consumer (DTC) laboratory tests are increasingly accessible to consumers with minimal or no involvement from healthcare professionals because the key players in the market are implementing various strategic activities such as mergers, partnerships, and product launches. Some of the key players in the market are Any Lab Test Now Inc., DirectLabs LLC, EasyDNA, Everlywell Inc., and Genesis Healthcare Co.
Direct-to-Consumer Laboratory Testing Market Leaders
-
Any Lab Test Now Inc.
-
DirectLabs, LLC.
-
EasyDNA
-
Everlywell, Inc.
-
Genesis Healthcare Co
*Disclaimer: Major Players sorted in no particular order
Direct-to-Consumer Laboratory Testing Market News
- September 2024: Redcliffe Labs, an Indian-based diagnostic lab, reported the launch of HealthEx tests, a non-invasive and reliable direct-to-consumer health test that comprehensively analyzes gut health. HealthEx is a blood test that evaluates an individual's DNA to provide health insights regarding potential risks one may develop due to current lifestyle.
- February 2024: Quest Diagnostics, a diagnostic information service provider, announced the introduction of a consumer-initiated PFAS chemicals test. This test allows individuals to check the levels of potentially harmful per- and polyfluorinated alkyl substances (PFAS) in their bodies. Additionally, the test panel includes an option for consumers to consult with a physician over the phone regarding the results. PFAS are also known as "forever chemicals".
Direct-to-Consumer Laboratory Testing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and market definitions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High Patient Convenience and Accessibilty
- 4.2.2 Growing Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Data Privacy Concerns
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Sample Type
- 5.1.1 Blood
- 5.1.2 Urine
- 5.1.3 Saliva
- 5.1.4 Other Sample Types (Stool and Other Body Fluids)
-
5.2 By Test Type
- 5.2.1 Routine Clinical Testing
- 5.2.2 Diabetes Testing
- 5.2.3 Genetic Testing
- 5.2.4 Thyroid Stimulating Hormone Testing
- 5.2.5 Other Test Types (Infectious Diseases Testing and Pregnancy Testing)
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Any Lab Test Now Inc.
- 6.1.2 DirectLabs LLC
- 6.1.3 EasyDNA
- 6.1.4 Everlywell Inc.
- 6.1.5 Genesis Healthcare Co.
- 6.1.6 Laboratory Corporation
- 6.1.7 PrivaPath Diagnostics
- 6.1.8 Genome Medical Inc.
- 6.1.9 Quest Diagnostics
- 6.1.10 Ulta Lab Tests LLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDirect-to-Consumer Laboratory Testing Industry Segmentation
As per the scope of the report, direct-to-consumer (DTC) lab tests are pathology tests marketed directly to the public. Consumers purchase and choose which tests to access. DTC testing does not require the recommendation or referral from a consulting doctor nor the facilitation of a public health program. The direct-to-consumer laboratory testing is segmented into sample type, test type, and geography. By sample type, the market is segmented into blood, urine, saliva, and other sample types. By application, the market is segmented into routine clinical testing, diabetes testing, genetic testing, thyroid-stimulating hormone testing, and other applications (infectious diseases testing and pregnancy testing). By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (in USD) for the above segments.
| By Sample Type | Blood | |
| Urine | ||
| Saliva | ||
| Other Sample Types (Stool and Other Body Fluids) | ||
| By Test Type | Routine Clinical Testing | |
| Diabetes Testing | ||
| Genetic Testing | ||
| Thyroid Stimulating Hormone Testing | ||
| Other Test Types (Infectious Diseases Testing and Pregnancy Testing) | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Direct-to-Consumer Laboratory Testing Market Research FAQs
How big is the Direct-to-Consumer Laboratory Testing Market?
The Direct-to-Consumer Laboratory Testing Market size is expected to reach USD 3.28 billion in 2024 and grow at a CAGR of 10.35% to reach USD 5.37 billion by 2029.
What is the current Direct-to-Consumer Laboratory Testing Market size?
In 2024, the Direct-to-Consumer Laboratory Testing Market size is expected to reach USD 3.28 billion.
Who are the key players in Direct-to-Consumer Laboratory Testing Market?
Any Lab Test Now Inc., DirectLabs, LLC., EasyDNA, Everlywell, Inc. and Genesis Healthcare Co are the major companies operating in the Direct-to-Consumer Laboratory Testing Market.
Which is the fastest growing region in Direct-to-Consumer Laboratory Testing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Direct-to-Consumer Laboratory Testing Market?
In 2024, the North America accounts for the largest market share in Direct-to-Consumer Laboratory Testing Market.
What years does this Direct-to-Consumer Laboratory Testing Market cover, and what was the market size in 2023?
In 2023, the Direct-to-Consumer Laboratory Testing Market size was estimated at USD 2.94 billion. The report covers the Direct-to-Consumer Laboratory Testing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Direct-to-Consumer Laboratory Testing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Direct-to-Consumer Laboratory Testing Industry Report
Statistics for the 2024 Direct-to-Consumer Laboratory Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Direct-to-Consumer Laboratory Testing analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
